1. Introduction
===============

Left main coronary artery disease is found in about 6% of patients undergoing coronary angiography.^\[[@R1]\]^ Unless being protected by collaterals or a patent graft, it has major cardiovascular mortality and morbidity among patients who present with acute cardiovascular events. Traditionally, coronary artery bypass surgery (CABG) is recommended as the sole treatment option, given its safety and efficacy compared with medical therapy, with significant improvement in the patient survival rate.^\[[@R2]\]^ However, nonsurgical candidates presented a challenge in treatment and led to the implementation of percutaneous coronary intervention (PCI) rescue with bare metal stents.^\[[@R3]--[@R5]\]^ Unfortunately, the mortality and revascularization rates were inferior to those of CABG, and the American College of Cardiology/American Heart Association guidelines, 2011, remained firm in stating that CABG is recommended for significant left main coronary artery stenosis, class 1 recommendation. However, the PCI approach is considered reasonable, class IIa recommendation, in favorable anatomical lesions or low SYNTAX score. The emergence of drug-eluting stents (DESs) has caused a major shift in interventional cardiology, and the issue of PCI versus CABG has become a topic of debate between interventional cardiologists and cardiac surgeons during the last 20 years. Randomized and nonrandomized trials in the DES era showed conflicting results with different follow-up durations. Small meta-analysis studies^\[[@R6],[@R7]\]^ that mainly recruited randomized trials were conducted in the past; however, the outcomes have been variable. We therefore conducted this large, updated meta-analysis study involving randomized and up-to-date published data to review the clinical outcomes between the 2 treatment modalities.

2. Methods
==========

The flow diagram for the meta-analysis is shown in Fig. [1](#F1){ref-type="fig"}. The study was based on previous published articles; therefore, no ethical approval or patient consent is needed. We used 4 databases for our research to collect appropriate studies (Table [1](#T1){ref-type="table"}).^\[[@R8]--[@R36]\]^ PubMed, Google Scholar, reference lists of relevant articles, and Medline were the primary tools used in our study. A total of 2 investigators including the author were involved in identifying the required studies up to September 2017. Steps were taken to prevent duplication. The following terms were used in our search: "left main PCI versus CABG," "drug-eluting stents, " "bypass surgery, " and "left main stenting. " Furthermore, the reference lists of all relevant studies were scrutinized to obtain more qualified studies. The same investigators independently extracted the data and clinical outcomes from the relevant studies to minimize errors or missing data. Studies were included if they compared PCI (strictly DESs) with CABG, had at least 1-year clinical follow-up, and were randomized and nonrandomized trials. Studies were excluded if they compared bare metal stents with CABG, targeted certain patients with chronic diseases, had unclear or difficult-to-extract outcomes, did not compare PCI with CABG, and assessed the outcome in patients who presented with acute coronary syndrome. The risk of bias for all included studies was assessed using the components proposed by the Cochrane Collaboration, which are random sequence generation, allocation concealment, blinding of outcome assessors, incomplete outcome data; and selective outcome reporting.^\[[@R37]\]^ The quality of randomized studies was assessed by the Jadad Score, which ranges from 0 to 5^\[[@R38]\]^. The randomized trials had score of 2 for lack of double-blind effect (Table [2](#T2){ref-type="table"}).^\[[@R8],[@R17],[@R24],[@R30],[@R32]\]^ On the other hand, the quality of observation studies was evaluated based on the Newcastle--Ottawa Scale form.^\[[@R39]\]^ A minimum score of 7 was considered high quality study (Table [3](#T3){ref-type="table"}).^\[[@R9]--[@R16],[@R18]--[@R23],[@R25]--[@R29],[@R31],[@R33]--[@R36]\]^ We calculated some of the clinical outcomes if reported with percentage numbers. Propensity score analysis data were included if available. The pooled data were analyzed with Review Manager Version 5.3 (RevMan software, available from <http://tech.cochrane.org/revman>). The primary outcomes were major adverse cardiovascular and cerebrovascular events (MACCE), stroke, all-cause mortality, myocardial infarction (MI), and revascularization after at least 1 year of follow-up. The definition of MACCE was reviewed carefully in each individual study, and it included revascularization in our analysis. Subgroup analysis for the same outcomes after at least 5 years of follow-up was also performed. The secondary outcomes of MACCE, stroke, all-cause mortality, MI, and revascularization during the hospital stay and at the 30-day period were analyzed. We used the Mantel--Haenszel statistical method with random effects. Effect size for individual clinical outcomes was estimated using odds ratios (ORs) and confidence intervals (CIs). The heterogeneity across studies was examined by using the Q test and quantified with the I^2^ test. A value of \>50% and a *P* value of \<.1 were considered significant. We conducted a sensitivity/meta-regression analysis and a leave-one-out study when appropriate to explain significant heterogeneity.
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###### 

Selected baseline characteristics of randomized trials and observational studies.
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###### 

Randomized studies quality assessment using Oxford Quality Scoring System.
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###### 

Newcastle--Ottawa scale (NOS) for assessing quality of observational studies.
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3. Results
==========

A total of 21,832 patients were included in our study, with 10,424 in the PCI/DES group versus 11,408 in the CABG group. We identified 5 randomized controlled trials and 24 observational studies of PCI/DES versus CABG for ULMCAD with at least 1 year of follow-up. The randomized controlled trials included the EXCEL trial (Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease), Nordic-Baltic-British Left Main Revascularization (NOBLE) trial (Percutaneous Coronary Angioplasty versus Coronary Artery Bypass Grafting in Treatment of Unprotected Left Main Stenosis), PRE-COMBAT trial---5 years (Bypass Surgery versus Angioplasty Using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease), SYNTAX trial (Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery), and the trial by Boudriot et al (Randomized Comparison of Percutaneous Coronary Intervention With Sirolimus-Eluting Stents Versus Coronary Artery Bypass Grafting in Unprotected Left Main Stem Stenosis). The baseline characteristics and follow-up duration of all included studies are summarized in Table [1](#T1){ref-type="table"}. We omitted the CUSTOMIZE trial (Appraise a Customized Strategy for Left Main Revascularization) because 10% of its patients did not receive DESs. The risk of bias of all included studies was summarized in Figs. [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}. Observational studies carried an expected risk of bias. However, they had high quality in their clinical design and data outcome (Table [3](#T3){ref-type="table"}).

![Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.](medi-97-e9909-g005){#F2}

![Risk of bias summary: review authors' judgements about each risk of bias item for each included study.](medi-97-e9909-g006){#F3}

There were no significant differences between the 2 groups in hospital MACCE (OR 0.42, 95% CI 0.14--1.23, *P* = .11), MI (OR 0.62, 95% CI 0.20--1.96, *P* = .42), and revascularization (OR 1.49, 95% CI 0.66--3.34, *P* = .33). However, PCI was found superior to CABG in terms of mortality (OR 0.33, 95% CI 0.12--0.90, *P* = .03) and stroke (OR 0.28, 95% CI 0.13--0.58, *P* = .0006) (Figs. [4](#F4){ref-type="fig"}--[8](#F8){ref-type="fig"}). The 30-day follow-up outcomes revealed a shift favoring PCI for MACCE (OR 0.52, 95% CI 0.38--0.72, *P* \< .0001), and MI (OR 0.65, 95% CI 0.43--0.99, *P* = .04) whereas the difference remained not significant for revascularization (OR 0.52, 95% CI 0.23--1.18, *P* = .12), and mortality (OR 0.68, 95% CI 0.32--1.45, *P* = .31) (Figs. [4](#F4){ref-type="fig"}--[8](#F8){ref-type="fig"}). A minimum of 1-year follow-up showed favorable outcomes for CABG in terms of MACCE (OR 1.42, 95% CI 1.27--1.59, *P* \< .00001), revascularization (OR 3.00, 95% CI 2.41--3.73, *P* \< .00001), and MI (OR 1.32, 95% CI 1.14--1.53, *P* = .0002), whereas the risk of stroke favored PCI (OR 0.52, 95% CI 0.37--0.72, *P* \< .0001) over CABG. Nonetheless, long-term mortality remained not significant between the 2 groups (OR 1.24, 95% CI 0.88--1.07, *P* = .21) (Figs. [4](#F4){ref-type="fig"}--[8](#F8){ref-type="fig"}).

![Forest plot of major cardiovascular and cerebrovascular events (MACCE) outcome in percutaneous coronary intervention (PCI) versus coronary artery bypass surgery (CABG) for unprotected left main coronary artery disease (ULMCAD). Forest plot shows the odd ratio (OR) of MACCE in PCI versus CABG during in hospital follow-up (A), 30-day follow-up (B), long-term follow-up ≥ 1 year (C), and subgroup ≥ 5 years follow-up (D).](medi-97-e9909-g007){#F4}
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![Forest plot of stroke outcome in percutaneous coronary intervention (PCI) versus coronary artery bypass surgery (CABG) for unprotected left main coronary artery disease (ULMCAD). Forest plot shows the odd ratio (OR) of stroke in PCI versus CABG during in hospital follow-up (A), 30-day follow-up (B), long-term follow-up ≥1 year (C), and subgroup ≥ 5 years follow-up (D).](medi-97-e9909-g011){#F8}

Pooled analysis of studies conducted for at least 5 years was then performed as a subgroup analysis to test the consistency of the primary outcome results beyond 1 year of follow-up and to increase the power of the study design. We found that CABG remained favorable over PCI in terms of revascularization (OR 2.86, 95% CI 2.19--3.74, *P* \< .00001) and MI (OR 1.42, 95% CI 1.0--2.01, *P* = .05). There was no difference in mortality (OR 0.83, 95% CI 0.60--1.15, *P* = .26) and MACCE (OR 1.22, 95% CI 0.95--1.56, *P* = .12). The risk of stroke remained low in the PCI group (OR 0.55, 95% CI 0.31--0.96, *P* = .03) (Figs. [4](#F4){ref-type="fig"}--[8](#F8){ref-type="fig"}).

A significant heterogeneity was noted in long-term (≥ 1 year) revascularization and stroke. For stroke, leave-one-out sensitivity analysis showed that the NOBLE trial played a major role in the high heterogeneity effect. On the other hand, no similar influence was found in the revascularization outcome; hence, meta-regression analysis was performed.

In the meta-regression analysis, a total of 5 baseline characteristics---number of male subjects, diabetes mellitus, hypertension, left ventricular ejection fraction, and SYNTAX score---were included in the analysis. The mean of SYNTAX score and left ventricular ejection fraction was calculated for each individual study in the long-term follow-up (≥ 1 year) group and the 5-year group (Supplemental Figures). SYNTAX score was the only covariant with a size effect between both groups. The long-term follow-up (≥ 1 year) group showed a regression coefficient of 0.067 (*P* = .005), and the 5-year follow-up group had a regression coefficient of 0.109 (*P* = .010). In other words, the lower the SYNTAX score, the lower relative risk of revascularization.

4. Discussion
=============

The advancements in medical technology have shifted the practice of cardiology to less invasive surgical interventions. The safety of PCI for ULMCAD has remained an issue of debate between cardiac surgeons and interventional cardiologists. To date, many observational studies and a few randomized trials have been conducted, with conflicting results. We conducted this meta-analysis of 29 studies including randomized trials, with the aim of addressing the safety and feasibility of PCI/DES in ULMCAD. Our review of 29 studies and 21,832 patients is, to our knowledge, the largest meta-analysis to address short-term (in-hospital and 30-day) and long-term follow-ups. Our findings clearly showed that PCI is safe and feasible during in-hospital and short-term follow-ups; however, it loses its potentiality after a minimum of 1 year of follow-up with more need for revascularization and increased numbers of MI events (Figure [5](#F5){ref-type="fig"}C, [7](#F7){ref-type="fig"}C). We noted a dramatic shift in clinical outcomes during the long-term follow-ups compared with the early phase, in-hospital, and 30-day follow-up periods. In the early phase, patients who underwent PCI tended to experience less stroke and MACCE (Figure [4](#F4){ref-type="fig"}B, [8](#F8){ref-type="fig"}B). These findings were supported by the EXCEL randomized trial (Table [1](#T1){ref-type="table"}), in which patients with CABG had high MACCE during the 30-day follow-up (HR 0.57, 95% CI 0.4--0.82, *P* = .002). Contrary to the EXCEL trial, our meta-analysis revealed that stroke and MI led to a high MACCE clinical outcome (Fig. [8](#F8){ref-type="fig"}), whereas MI (HR 0.63, 95% CI 0.42--0.95, *P* = .02) played a major role in the EXCEL trial. Of note, our early phase results were heavily based on the EXCEL trial which accounted for 70% to 90% of the analysis. Unfortunately, this short-term noninferiority of PCI to CABG started to lose its potentiality after 1 year of follow-up with more need for revascularization (Fig. [5](#F5){ref-type="fig"}). Boudriot et al (Table [1](#T1){ref-type="table"}) conducted a 1-year randomized trial in which repeat revascularization in the PCI group was inferior to CABG. However, it might be fair to point out that routine angiographic follow-up was 15% more frequently conducted in patients who underwent PCI, and this might have led to the more revascularization observed in the study. Additionally, about two-thirds of the reported lesions were in the distal segment of the ULMCAD. Anatomically, the left main coronary artery is divided into 3 segments: ostial, mid-shaft, and distal bifurcation with a smaller diameter than the proximal segment. Thus, the proximal segment allows interventional cardiologists to use larger-diameter stents with a low rate of restenosis. Furthermore, the treatment of the distal left main bifurcation diseases implies the need for more complex and technically demanding bifurcation techniques. In particular, the need for 2- stent approach has shown a higher incidence of procedure- related complications and unfavorable outcomes.^\[[@R40]\]^ A meta-analysis of 16 trials involving PCI for ULMCAD identified distal lesions as the most significant predictor of repeated revascularization and overall MACCE outcomes.^\[[@R41]\]^ Moreover, previous studies have reported better outcomes for proximal segment stenting in ULMCAD.^\[[@R42],[@R43]\]^ It is noteworthy to mention that about 80% of the analyzed studies (PCI group) included distal bifurcation lesions, which, in other words, may explain this unfavorable outcome in the PCI group.

Moreover, we noted an increased incidence of MI after long-term follow-up in the PCI group compared with the CABG group (OR 1.32, 95% CI 1.14--1.53, *P* = .0002) (Fig. [7](#F7){ref-type="fig"}C) which, in turn, may represent the high revascularization demand possibly related to true angina symptoms. The MI outcome was also sustained after subgroup analysis of studies with ≥5 years of follow-up. Our finding is similar to that of the NOBLE trial (Table [1](#T1){ref-type="table"}) (HR 2.88, 95% CI 1.40--5.90, *P* = .004). This advantage of CABG might be achieved by detouring blood supply over the long lesion segment, which, to some extent, protects against target-lesion and de novo lesion MIs. However, no significant difference in MI was found in the EXCEL (HR 0.93, 95% CI 0.67--1.28, *P* = .64) and SYNTAX (HR 1.67, 95% CI 0.91--3.10, *P* = .10) trials, with a noninferiority outcome between the 2 groups (Table [1](#T1){ref-type="table"}). This discrepancy between trials is difficult to explain; however, the definition of MI is not universal owing its own limitations when applied to clinical outcome.

Numerous previous studies found no statistical difference in the long-term mortality between the 2 groups. This observation is supported by the EXCEL (HR 1.34, 95% CI 0.94--1.91, *P* = .11), SYNTAX (HR 0.88, 95% CI 0.58--1.32, *P* = .53), and NOBLE (HR 1.04, 95% CI 0.65--1.67, *P* = .86) trials (Table [1](#T1){ref-type="table"}). Our study agrees with previous trials, although the mortality rate was high among the CABG population during in-hospital stay (Fig. [6](#F6){ref-type="fig"}A and C). A number of preoperative and intraoperative factors have been demonstrated to influence the operative mortality in CABG per se, including comorbid conditions. In the United States, the mortality rate after CABG between 1997 and 2001 averaged about 2% to 5% in general.^\[[@R44],[@R45]\]^ However, after a minimum of 30 days of follow-up, both groups tended to have the same mortality rate even after 5 years of follow-up (Fig. [6](#F6){ref-type="fig"}D). In a real-world comparison, Yi et al (Table [1](#T1){ref-type="table"}) conducted a prospective study with a matching patient cohort, comparing off-pump bypass procedures versus DES in ULMCAD. Again, the authors found no difference in mortality between the 2 groups during 5 years of follow-up. On the contrary, Qin et al (Table [1](#T1){ref-type="table"}) reported a different result with a higher mortality rate among the CABG group, resulting from the high cardiac death after long-term follow-up (1.7% PCI vs 6.4% CABG, *P* = .01). Nevertheless, we noted that the left internal mammary artery was used below the usual percentile, which might be a factor in the different clinical outcomes.

The risk of stroke, as one of the most devastating complications, remained high in the CABG group even after long-term follow-up. However, including the NOBLE trial, the heterogeneity effect increased among the compared studies, secondary with the increase in stroke in the PCI group. Although no clear reasons were found, it was noted that most strokes occurred mainly after 1 year, coinciding with the discontinuation of dual antiplatelet therapy. Similar to our finding, a meta-analysis study by Athappan et al^\[[@R46]\]^ found that PCI is superior to CABG in terms of stroke outcome even after 5 years of follow-up (OR 0.27, 95% CI 0.13--0.55, *P* = .00). Moreover, many nonrandomized trials showed noninferiority or even superiority of PCI over CABG when the risk of stroke was considered. Two variables are believed to play a major role in the stroke incidence after bypass surgery: cerebral embolism due to the manipulation of aortic atherosclerotic plaques during surgery^\[[@R47],[@R48]\]^ and cerebral hypoperfusion during surgery.^\[[@R49],[@R50]\]^ Therefore, the prevalence of atherosclerotic disease among patients with ULMCAD highlights the importance of identifying vulnerable patients and is crucial in weighing the benefits of performing PCI during decision making.

The definition of MACCE was somehow variable among the different studies. We analyzed data from studies that defined MACCE strictly as a composite of MI, stroke, all-cause mortality, and revascularization. In our study, MACCE yielded different results after each period of follow-up. It seems that PCI is not inferior to CABG during in-hospital stay, and even achieved superiority after a minimum of 30-day follow-up (OR 0.52, 95% CI 0.38--0.72, *P* \< .0001). Nevertheless, this potential benefit shifted to CABG after long-term follow-up (OR 1.42, 95% CI 1.27--1.59, *P* \< .00001) (Fig. [4](#F4){ref-type="fig"}). In a retrospective study conducted by Shimizu et al (Table [1](#T1){ref-type="table"}), the MACCE-free survival rate was better (*P* = .033) in the CABG group (CABG 82.2% vs DES 62.6%) at 2 years. However, analysis of data extracted from studies of ≥5 years follow-up yielded different outcomes, and no statistical difference was found between the 2 groups (OR 1.22, 95% CI 0.95--1.56, *P* = .12) (Fig. [4](#F4){ref-type="fig"}D). The latter finding is in agreement with the SYNTAX trial (HR 1.23, 95% CI 0.95--1.59, *P* = .12). Contrary to our finding, MACCE remained favorable in the PCI group in a 5-year meta-analysis study conducted by Athappan et al^\[[@R46]\]^ (OR 0.64, 95% CI 051--0.8, *P* = .00). However, more articles were included in our analysis, which increased the study power effect. Overall, and given the inconsistent results among different studies, we can conclude that PCI remained at least noninferior to CABG in terms of MACCE after long-term monitoring. The strict definition of MACCE in our study improved the reliability and enhanced the interpretation of the MACCE outcome.

Our study has some limitations. First, the inclusion and exclusion criteria used may have created unintentional bias. Second, the observational studies carried inevitable high risk selection bias. Third, searches of the current databases still may not include all published studies with more negative results. Fourth, the in-hospital and 30-day follow-up outcomes were not reported by many studies, thus minimizing the analytical power of results. Fifth, although the significant heterogeneity noted in revascularization outcome was further explored, other underlying clinical variables may have been overlooked. Sixth, the definition of MI tended to vary among studies and thereby has its own limitations in clinical interpretation. Seventh, data of intravascular ultrasound practice were absent among a large proportion of the studies, making data analysis inaccurate, as they were not included in our meta-regression analysis.

In conclusion, compared with CABG, PCI/DES in ULMCAD was associated with increases in revascularization and MI during long-term follow-up; however, it showed a good safety profile during the short-term follow-up. It is reasonable to use the SYNTAX score to help guide decision making.
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